Back to All Working Groups

The International Working Group for Prognosis in MDS (IWG-PM) consists of a group of international investigators aligned through the MDS Foundation whose focus is aimed at defining the clinical and biologic features of MDS thus providing the foundation for understanding the nature and potential for progression of this spectrum of disorders. To this end the group has generated programs leading to seminal projects and publications characterizing and classifying the disease. Current group investigations include determining the impact of mutational features that further delineate disease status and potential therapeutic targets providing novel treatment approaches for MDS.

Click here to view members

MDS Risk Assessment Calculators*

The IWG-PM under the aegis of the MDS Foundation, Inc. has developed two prognostic tools, the IPSS-M and IPSS-R Calculators, to determine a patient’s risk of progressing to Acute Myeloid Leukemia (AML).

NEW IPSS-M Calculator

The IPSS-M is the newest MDS prognosis calculator that combines genomic profiling with hematologic and cytogenetic parameters, improving the risk stratification of patients with MDS. This is a valuable tool for clinical decision-making, offering the prospect of tailoring diagnosis and therapeutic interventions to each patient’s molecular profile.

Click below to access the calculator. iOS and Android apps coming soon.

IPSS-M Calculator

IPSS-M R Package

IPSS-R Calculator

The IPSS-R is the current MDS prognosis calculator that combines hematologic and cytogenetic parameters to determine an MDS patient’s risk stratification. This calculator tool includes clinical features of marrow blasts, cytogenetics, depth of cytopenias and age as well as the additive differentiate features for patient survival of performance status, serum ferritin, LDH, beta-2 micro globulin and marrow fibrosis.

IPSS-R Calculator

Google Play Store
Click here to download the MDS IPSS-R Calculator app

Current IWG-PM Projects

Project: Clinical characterization/classification of MDS

Clinical characterization/classification of MDS – an international group of researchers involved in patient classification, stratification, and prognosis to refine the currently accepted and utilized prognostic scoring systems (IPSS, WPSS) and propose prognostic scoring systems into an improved internationally accepted system.

Publications

1. Kuendgen A, Tuechler T, Nomdedeu M, et al…Sanz G. Therapy-related MDS deserve specific diagnostic sub-classification and risk-stratification – An approach to classification of t-MDS. Leukemia 2021:35, 835-849.
2. Nomdedeu M, Tuechler H, Kuendgen A, et al…Haase D. Cytogenetic findings in therapy-related MDS – relation with primary disease and therapy. Proc MDS Foundation Symposium, Copenhagen, May 2019, #127.
3. Greenberg PL, Tuechler H, Schanz J, Sanz G, et al. Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes. Blood 120: 2454-2465, 2012.
4. Della Porta M, Tuechler H, Malcovati L, Schanz J, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia 29: 1502-1513, 2015.
5. Pfeilstoecker M, Tuechler H, Schanz J, Sanz G, et al. Time-Dependent Changes in Mortality and Transformation Risk in Myelodysplastic Syndromes. Blood 128: 902-910, 2016.
6. Miyazaki Y, Tuechler H, Sanz G, Schanz J, et al. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research 73: 51-57, 2018.
7. Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero, G, et al. Therapy-related Myelodysplastic Syndromes deserve specific diagnostic sub-classification and risk-stratification – An approach to classification of patients with t-MDS. Leukemia 2020, in press.
8. Nomdedeu M, Tuechler H, Kuendgen A, et al. Cytogenetic findings in therapy-related MDS – relation with primary disease and therapy. Proc MDS Foundation Symposium, Copenhagen, May 2019.

Project:  Molecular classification of MDS Subtypes—Retrospective analysis

Molecular classification of MDS Subtypes – the development of a comprehensive risk algorithm that considers the composite molecular and clinical parameters that define a patient’s disease to capture more accurately patients with higher risk disease early; identify molecular patient subgroups that benefit from specific therapeutic intervention strategies (i.e hypomethylating agents) and thus deliver more effective treatment options in MDS – Retrospective analysis

Publications

1. Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, et al…Cazzola M. SF3B1-mutant MDS as a distinct disease subtype – A Proposal IWG-PM. Blood 2020, 136:157-1704.
2. Haase DT, Stevenson K, Neuberg D, Maciejewski J, et al. TP53 Mutation Status Divides Myelodysplastic Syndromes with Complex Karyotypes into Distinct Prognostic Risk Groups. Leukemia 33:1747-1758, 2019.
3. Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, et al.  SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype – A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Blood 2020, in press.

Project:  IWG-PM/Molecular Project: Molecular/Clinical classification of MDS—Prospective analysis

Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, et al Molecular International Prognosis Scoring System for Myelodysplastic Syndromes (IPSS-M). Proc ASH 2021, Atlanta, December, #61

Molecular classification of MDS Subtypes – the development of a comprehensive risk algorithm that considers the composite molecular and clinical parameters that define a patient’s disease to capture more accurately patients with higher risk disease early; identify molecular patient subgroups that benefit from specific therapeutic intervention strategies (i.e hypomethylating agents) and thus deliver more effective treatment options in MDS – Prospective analysis

Coordinating Committee: Elli Papaemmanuil, Ben Ebert, Rafael Bejar, Peter Greenberg

Oversight Steering Committee: Ben Ebert, Peter Greenberg, Elli Papaemmanuil, Rafael Bejar, Mario Cazzola, Luca Malcovati, Detlef Haase, Joop Jansen, Torsten Haferlach, Eva Hellstrom-Lindberg, Seishi Ogawa, Arjan van de Loosdrecht, Robert Hasserjian

Web-calculator developers: Juan Esteban Arango Ossa, Elsa Bernard, Peter Greenberg, Elli Papaemmanuil, Gary Nolan, James Badman, Tom Penfold, Nevena Krstic, Tracey Iraca and Lea Harrison

Publications

1. Bernard  E, Tuechler H, Greenberg PL, Hasserjian RP, et al,…, Ebert BL , Bejar R, Malcovati L, Cazzola M, Ogawa S, Hellström-Lindberg E, Papaemmanuil E. Molecular International Prognosis Scoring System for MDS (IPSS-M). Proc ASH 2021, #61, Atlanta, December
2. Bernard E, Nannya Y, Hasserjian, et al, …, Papaemmanuil E. Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in MDS. Nature Medicine 2020, 26:2549-2556
3. Bernard E, Nannya Y, Hasserjian R, Devlin S, Tuechler H, et al. Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes in press.
4. Papaemmanuil E, Bernard, et al. Classification and personalized prognosis in MDS. MDS Foundation Symposium, ASH meeting, 2019 Orlando, December.

Latest News Regarding the Molecular Mutation Project of the International Working Group for Prognosis in MDS (IWG-PM) – Read More

*Data for the IPSS-R & IPSS-M calculators are derived from:

• Bernard  E, Tuechler H, Greenberg PL, et al, The Molecular International Prognosis Scoring System (IPSS-M) for risk stratification in myelodysplastic syndromes. New Eng J Med Evidence. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008. Study supported by the MDS Foundation.
• Greenberg P, Tuechler H, Schanz J, et al, Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes. Blood 120: 2454-2465, 2012.